<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: A single nucleotide polymorphism located in the 3'-untranslated region of the KRAS oncogene (KRAS variant; rs61764370) disrupts a let-7 miRNA binding and was recently reported to act as a genetic marker for increased risk of developing human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to investigate an association of the KRAS variant with <z:hpo ids='HP_0003745'>sporadic</z:hpo> and familial <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">breast tumor</z:e> characteristics </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Genotyping was accomplished in 530 <z:hpo ids='HP_0003745'>sporadic</z:hpo> postmenopausal <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cases, 165 familial <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cases (including N = 29, who test positive for BRCA1/2 mutations) and 270 postmenopausal control women using the flurogenic 5' nuclease assay </plain></SENT>
<SENT sid="3" pm="."><plain>Information on hormone replacement therapy (HRT) use and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> characteristics in <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cases was ascertained from a postal questionnaire and pathology reports, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Associations between the KRAS genotype and <z:hpo ids='HP_0003002'>breast cancer</z:hpo> or <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">breast tumor</z:e> characteristics were assessed using chi-square test and logistic regression models </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: No evidence of association was observed between the KRAS variant and risk of <z:hpo ids='HP_0003745'>sporadic</z:hpo> and familial <z:hpo ids='HP_0003002'>breast cancer</z:hpo> - either among BRCA carriers or non-BRCA carriers </plain></SENT>
<SENT sid="6" pm="."><plain>The KRAS variant was statistically significantly more often associated with human epidermal growth factor receptor 2 (HER2) - positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of higher histopathologic grade </plain></SENT>
<SENT sid="7" pm="."><plain>However, both associations were detected only in HRT users </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Our data do not support the hypothesis that the KRAS variant rs61764370 is implicated in the aetiology of <z:hpo ids='HP_0003745'>sporadic</z:hpo> or of familial <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>In postmenopausal women using HRT, the KRAS variant might lead to HER2 overexpressed and poorly-differentiated <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">breast tumors</z:e>, both indicators of a worse prognosis </plain></SENT>
</text></document>